Zacks: Analysts Anticipate ICU Medical, Inc. (NASDAQ:ICUI) Will Announce Quarterly Sales of $546.80 Million

Wall Street brokerages forecast that ICU Medical, Inc. (NASDAQ:ICUIGet Rating) will post $546.80 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for ICU Medical’s earnings, with the highest sales estimate coming in at $563.60 million and the lowest estimate coming in at $530.00 million. ICU Medical reported sales of $318.05 million in the same quarter last year, which indicates a positive year-over-year growth rate of 71.9%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that ICU Medical will report full-year sales of $2.40 billion for the current financial year, with estimates ranging from $2.38 billion to $2.41 billion. For the next financial year, analysts anticipate that the business will report sales of $2.46 billion, with estimates ranging from $2.45 billion to $2.48 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for ICU Medical.

ICU Medical (NASDAQ:ICUIGet Rating) last announced its earnings results on Thursday, February 24th. The medical instruments supplier reported $1.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.41 by $0.11. The business had revenue of $340.53 million for the quarter, compared to the consensus estimate of $323.90 million. ICU Medical had a net margin of 7.84% and a return on equity of 8.58%. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.52 earnings per share.

ICUI has been the subject of a number of recent analyst reports. StockNews.com began coverage on shares of ICU Medical in a research note on Thursday, March 31st. They issued a “strong-buy” rating for the company. Zacks Investment Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 30th. Finally, Raymond James dropped their target price on shares of ICU Medical from $286.00 to $265.00 and set an “outperform” rating for the company in a report on Monday, February 28th.

In other news, CEO Vivek Jain sold 36,000 shares of the stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $240.00, for a total value of $8,640,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.10% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the company. Thrivent Financial for Lutherans increased its position in ICU Medical by 51.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 16,858 shares of the medical instruments supplier’s stock worth $3,934,000 after purchasing an additional 5,698 shares in the last quarter. New York State Teachers Retirement System increased its holdings in ICU Medical by 11.0% during the 4th quarter. New York State Teachers Retirement System now owns 27,851 shares of the medical instruments supplier’s stock worth $6,610,000 after purchasing an additional 2,761 shares during the last quarter. Quantinno Capital Management LP purchased a new stake in ICU Medical during the 3rd quarter worth approximately $236,000. Squarepoint Ops LLC increased its holdings in ICU Medical by 534.3% during the 3rd quarter. Squarepoint Ops LLC now owns 7,155 shares of the medical instruments supplier’s stock worth $1,670,000 after purchasing an additional 6,027 shares during the last quarter. Finally, Segall Bryant & Hamill LLC increased its holdings in shares of ICU Medical by 10.6% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 180,189 shares of the medical instruments supplier’s stock valued at $42,053,000 after acquiring an additional 17,304 shares during the last quarter. Institutional investors and hedge funds own 93.36% of the company’s stock.

NASDAQ ICUI opened at $226.40 on Thursday. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of 47.76 and a beta of 0.48. The company’s 50-day simple moving average is $226.59 and its two-hundred day simple moving average is $229.34. ICU Medical has a one year low of $183.39 and a one year high of $282.00.

ICU Medical Company Profile (Get Rating)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs.

Featured Articles

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.